Reviva Pharmaceuticals Holdings Inc
RVPH0.599USD
+0.014+2.41%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
57.70MMarket Cap
LossP/E TTM
More Details of Reviva Pharmaceuticals Holdings Inc Company
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
Reviva Pharmaceuticals Holdings Inc Info
Ticker SymbolRVPH
Company nameReviva Pharmaceuticals Holdings Inc
IPO dateOct 18, 2018
CEOBhat (Laxminarayan)
Number of employees14
Security typeOrdinary Share
Fiscal year-endOct 18
Address10080 N Wolfe Road
CityCUPERTINO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code95014
Phone14085018881
Websitehttps://revivapharma.com/
Ticker SymbolRVPH
IPO dateOct 18, 2018
CEOBhat (Laxminarayan)
Company Executives of Reviva Pharmaceuticals Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Laxminarayan Bhat, Ph.D.
Dr. Laxminarayan Bhat, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.48M
--
Mr. Parag Saxena
Mr. Parag Saxena
Independent Chairman of the Board
Independent Chairman of the Board
871.34K
--
Mr. Narayan Prabhu
Mr. Narayan Prabhu
Chief Financial Officer
Chief Financial Officer
100.00K
--
Mr. Purav Patel
Mr. Purav Patel
Independent Director
Independent Director
59.72K
-0.53%
Mr. Leslie D. (Les) Funtleyder
Mr. Leslie D. (Les) Funtleyder
Independent Director
Independent Director
--
--
Dr. Richard Margolin
Dr. Richard Margolin
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Laxminarayan Bhat, Ph.D.
Dr. Laxminarayan Bhat, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.48M
--
Mr. Parag Saxena
Mr. Parag Saxena
Independent Chairman of the Board
Independent Chairman of the Board
871.34K
--
Mr. Narayan Prabhu
Mr. Narayan Prabhu
Chief Financial Officer
Chief Financial Officer
100.00K
--
Mr. Purav Patel
Mr. Purav Patel
Independent Director
Independent Director
59.72K
-0.53%
Mr. Leslie D. (Les) Funtleyder
Mr. Leslie D. (Les) Funtleyder
Independent Director
Independent Director
--
--
Dr. Richard Margolin
Dr. Richard Margolin
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Diadema Partners LP
2.18%
Bhat (Laxminarayan)
2.16%
The Vanguard Group, Inc.
1.67%
Millennium Management LLC
1.49%
Vedanta Partners LLC
1.24%
Other
91.26%
Shareholders
Shareholders
Proportion
Diadema Partners LP
2.18%
Bhat (Laxminarayan)
2.16%
The Vanguard Group, Inc.
1.67%
Millennium Management LLC
1.49%
Vedanta Partners LLC
1.24%
Other
91.26%
Shareholder Types
Shareholders
Proportion
Hedge Fund
4.45%
Individual Investor
3.06%
Investment Advisor
2.59%
Corporation
1.24%
Investment Advisor/Hedge Fund
0.84%
Research Firm
0.38%
Venture Capital
0.09%
Other
87.36%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
89
13.84M
12.13%
+1.12M
2025Q2
89
16.55M
34.61%
-235.10K
2025Q1
92
14.72M
30.68%
+452.96K
2024Q4
80
15.12M
43.73%
-664.59K
2024Q3
70
15.01M
45.14%
+2.17M
2024Q2
67
11.80M
40.19%
-1.16M
2024Q1
65
10.54M
37.76%
-219.65K
2023Q4
63
10.24M
38.88%
+2.34M
2023Q3
54
7.63M
33.67%
-432.21K
2023Q2
51
7.71M
36.30%
+1.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Diadema Partners LP
2.74M
2.84%
+2.08M
+320.37%
Jun 30, 2025
Bhat (Laxminarayan)
2.48M
2.58%
--
--
Sep 24, 2025
The Vanguard Group, Inc.
1.80M
1.87%
--
--
Jun 30, 2025
Millennium Management LLC
1.49M
1.54%
-46.27K
-3.02%
Jun 30, 2025
Vedanta Partners LLC
1.43M
1.48%
--
--
Sep 22, 2025
Saxena (Parag)
871.34K
0.9%
--
--
Sep 22, 2025
Persistent Asset Partners Limited
641.17K
0.67%
+480.86K
+299.96%
Jun 30, 2025
Geode Capital Management, L.L.C.
448.20K
0.47%
+29.06K
+6.93%
Jun 30, 2025
Susquehanna International Group, LLP
96.91K
0.1%
-134.54K
-58.13%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Reviva Pharmaceuticals Holdings Inc?
The top five shareholders of Reviva Pharmaceuticals Holdings Inc are:
Diadema Partners LP holds 2.74M shares, accounting for 2.84% of the total shares.
Bhat (Laxminarayan) holds 2.48M shares, accounting for 2.58% of the total shares.
The Vanguard Group, Inc. holds 1.80M shares, accounting for 1.87% of the total shares.
Millennium Management LLC holds 1.49M shares, accounting for 1.54% of the total shares.
Vedanta Partners LLC holds 1.43M shares, accounting for 1.48% of the total shares.
Diadema Partners LP holds 2.74M shares, accounting for 2.84% of the total shares.
Bhat (Laxminarayan) holds 2.48M shares, accounting for 2.58% of the total shares.
The Vanguard Group, Inc. holds 1.80M shares, accounting for 1.87% of the total shares.
Millennium Management LLC holds 1.49M shares, accounting for 1.54% of the total shares.
Vedanta Partners LLC holds 1.43M shares, accounting for 1.48% of the total shares.
What are the top three shareholder types of Reviva Pharmaceuticals Holdings Inc?
The top three shareholder types of Reviva Pharmaceuticals Holdings Inc are:
Diadema Partners LP
Bhat (Laxminarayan)
The Vanguard Group, Inc.
Diadema Partners LP
Bhat (Laxminarayan)
The Vanguard Group, Inc.
How many institutions hold shares of Reviva Pharmaceuticals Holdings Inc (RVPH)?
As of 2025Q3, 89 institutions hold shares of Reviva Pharmaceuticals Holdings Inc, with a combined market value of approximately 13.84M, accounting for 12.13% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -22.48%.
What is the biggest source of revenue for Reviva Pharmaceuticals Holdings Inc?
In --, the -- business generated the highest revenue for Reviva Pharmaceuticals Holdings Inc, amounting to -- and accounting for --% of total revenue.
